infigratinib
bridgebio pharmaceutical,helsinn,qed therapeutics
helsinn is excited that a poster is being presented today describing the design of the ongoing proof 301 study of #infigratinib in advanced #cholangiocarcinoma today at the congress. #cca 
Helsinn is a fully integrated, global biopharma company focused on improving the lives of cancer patients all over the world. https://t.co/NUziRuBgtr